#gskplc — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #gskplc, aggregated by home.social.
-
Chinese biopharma stocks jump as U.S. plans to continue drug licensing deals
A young female worker in protective gear carefully carries a container …
#NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Business #AkesoInc #BreakingNews:Markets #businessnews #CSPCPHARMACEUTICALGROUPLIMITED #GSKplc #HUTCHMED(China)Ltd #Inc. #InnoventBiologics #iSharesBiotechnologyETF #iSharesMSCIChinaETF #Markets #PfizerInc #SinoBiopharmaceuticalLtd #SpdrS&PBiotechEtf
https://www.newsbeep.com/us/855237/ -
Chinese biopharma stocks jump as U.S. plans to continue drug licensing deals
A young female worker in protective gear carefully carries a container …
#NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Business #AkesoInc #BreakingNews:Markets #businessnews #CSPCPHARMACEUTICALGROUPLIMITED #GSKplc #HUTCHMED(China)Ltd #Inc. #InnoventBiologics #iSharesBiotechnologyETF #iSharesMSCIChinaETF #Markets #PfizerInc #SinoBiopharmaceuticalLtd #SpdrS&PBiotechEtf
https://www.newsbeep.com/us/855237/ -
GSK Inks $750M Deal to Add Experimental Blood Cancer Therapy
GSK plc GSK has entered into an agreement to acquire an investigational trispecific T-cell engager (TCE) from Chimagen…
#EuropeSays #Britain #Europe #EU #GSK #bloodcancer #ChimagenBiosciences #GSKplc #multiplemyeloma #TCE #ZacksInvestmentResearch
https://www.europesays.com/britain/124675/ -
https://www.europesays.com/britain/124675/ GSK Inks $750M Deal to Add Experimental Blood Cancer Therapy #BloodCancer #ChimagenBiosciences #GSK #GSKPlc #MultipleMyeloma #TCE #ZacksInvestmentResearch
-
GSK Presents Jideytro Data for Potential Use in First-Line NSCLC
GSK plc GSK announced positive data from the registrational phase I/II ARROS-1 study evaluating its oncology drug, Jideytro…
#EuropeSays #Britain #Europe #EU #GSK #GSKplc #Jideytro #nsclc #OncologyDrug #Patients #ZacksInvestmentResearch #ZacksRank
https://www.europesays.com/britain/123943/ -
https://www.europesays.com/britain/123943/ GSK Presents Jideytro Data for Potential Use in First-Line NSCLC #GSK #GSKPlc #Jideytro #nsclc #OncologyDrug #Patients #ZacksInvestmentResearch #ZacksRank